<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03606187</url>
  </required_header>
  <id_info>
    <org_study_id>SGEN-2018PM2</org_study_id>
    <nct_id>NCT03606187</nct_id>
  </id_info>
  <brief_title>Stimgenics Open-Label, Post Market Study</brief_title>
  <acronym>SGX-SCS-RCT</acronym>
  <official_title>Stimgenics Open-Label, Post Market Study: A Clinical Trial to Study the Effects of Stimgenics Spinal Cord Stimulation (SGX-SCS) Programs in Treating Intractable Chronic Back Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stimgenics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stimgenics LLC</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this investigational study is to study the effects of Stimgenics Spinal Cord&#xD;
      Stimulation (SGX-SCS) in subjects with chronic, intractable pain of the trunk with lower limb&#xD;
      pain, including unilateral or bilateral pain associated with the following conditions: failed&#xD;
      back surgery syndrome, intractable low back pain and leg pain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label prospective, randomized, controlled, multi-center study comparing&#xD;
      Stimgenics Spinal Cord Stimulation (SGX-SCS) programming approach to Standard SCS programming&#xD;
      approach.&#xD;
&#xD;
      Subjects meeting study entrance criteria will be randomized in a 1:1 ratio to one of two&#xD;
      study treatment groups:&#xD;
&#xD;
        -  Test treatment group with SGX-SCS programming approach&#xD;
&#xD;
        -  Control treatment group with Standard SCS programming approach&#xD;
&#xD;
      Data at follow-up visits will be compared between the two treatment groups, and in reference&#xD;
      to baseline assessments collected at the beginning of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 26, 2018</start_date>
  <completion_date type="Actual">July 22, 2020</completion_date>
  <primary_completion_date type="Actual">November 8, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Percentage of Individual Responders</measure>
    <time_frame>3 months</time_frame>
    <description>Percentage of Participants with a 50% decrease in back pain at 3 months compared to baseline. Pain rating will be measured on the 10 cm Visual Analog Scale (VAS). Change in back pain score will be used to determine individual responder (e.g., 50% reduction in VAS compared to Baseline VAS).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Individual Responders</measure>
    <time_frame>3 months</time_frame>
    <description>The percentage of Individual Responders (50% reduction in pain score rated on a Visual Analog Scale); Test for superiority</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Back Pain Score</measure>
    <time_frame>3 months</time_frame>
    <description>Comparison of change from Baseline in back pain score (using Visual Analog Scale 0.0-10.0cm) determined at the 3- and 6-month visit after device activation, between test and control in a statistical test of non-inferiority. This is calculated as: Change from Baseline in Back Pain VAS = 3-Month Visit Pain VAS - Baseline Pain VAS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 Months Comparison of Back Pain Treatment Success</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison of Back Pain Treatment Success (responder rate), measured as subjects with at least a 50% reduction in Back Pain Visual Analog Scale (VAS), evaluated at 6 months after device activation, between test and control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oswestry Disability Index (ODI)</measure>
    <time_frame>3 months</time_frame>
    <description>Oswestry Disability Index (ODI) evaluated at 3 months visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>3 months</time_frame>
    <description>Frequency of treatment emergent adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Chronic Low Back Pain</condition>
  <arm_group>
    <arm_group_label>Test Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to this arm will receive test treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized to this arm will receive control treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Stimgenics SCS Programming Approach</intervention_name>
    <description>Stimgenics SCS Programming approach Using Intellis(TM) SCS system</description>
    <arm_group_label>Test Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard SCS Programming Approach</intervention_name>
    <description>Standard SCS Programming approach using Intellis(TM) SCS system</description>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be a candidate for SCS system (trial and implant) per labeled indication (back and leg&#xD;
             pain)&#xD;
&#xD;
          2. Has an average back pain intensity â‰¥ 5.0 cm on the 10.0 cm Visual Analog Scale (VAS)&#xD;
             at the time of enrollment with moderate to severe chronic leg pain&#xD;
&#xD;
          3. Be willing and capable of giving written informed consent to participate in this&#xD;
             clinical study based on voluntary agreement after a thorough explanation of the&#xD;
             subject's participation has been provided.&#xD;
&#xD;
          4. Be willing and capable of subjective evaluation, read and understand English-written&#xD;
             questionnaires, and read, understand and sign the written inform consent in English.&#xD;
&#xD;
          5. Be 18 years of age or older at the time of enrollment&#xD;
&#xD;
          6. Be on a stable pain medication regime, as determined by the study investigator, for at&#xD;
             least 30 days prior to enrolling in this study&#xD;
&#xD;
          7. Be willing to not increase pain medications from baseline through the 3-Month Visit&#xD;
&#xD;
          8. Be willing and able to comply with study-related requirements, procedures, and visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has a medical, anatomical, and/or psychosocial condition that is contraindicated for&#xD;
             commercially available IntellisTM SCS systems as determined by the Investigator&#xD;
&#xD;
          2. Be concurrently participating in another clinical study&#xD;
&#xD;
          3. Has an existing active implanted device such as a pacemaker, another SCS unit,&#xD;
             peripheral nerve stimulator, and/or drug delivery pump, etc.&#xD;
&#xD;
          4. Has pain in other area(s) and/or medical condition requiring the regular use of&#xD;
             significant pain medications that could interfere with accurate pain reporting, study&#xD;
             procedures, and/or confound evaluation of study endpoints, as determined by the&#xD;
             Investigator&#xD;
&#xD;
          5. Has mechanical spine instability as determined by the Investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>StimGenics</name>
      <address>
        <city>Bloomington</city>
        <state>Illinois</state>
        <zip>61701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 12, 2018</study_first_submitted>
  <study_first_submitted_qc>July 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2018</study_first_posted>
  <results_first_submitted>November 8, 2020</results_first_submitted>
  <results_first_submitted_qc>February 10, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 2, 2021</results_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Back Pain, Spinal Cord Stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 2, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT03606187/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Test Arm</title>
          <description>Subjects randomized to this arm will receive test treatment&#xD;
Stimgenics SCS Programming Approach: Stimgenics SCS Programming approach Using Intellis(TM) SCS system</description>
        </group>
        <group group_id="P2">
          <title>Control Arm</title>
          <description>Subjects randomized to this arm will receive control treatment&#xD;
Standard SCS Programming Approach: Standard SCS Programming approach Using Intellis(TM) SCS system</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Test Arm</title>
          <description>Subjects randomized to this arm will receive test treatment&#xD;
Stimgenics SCS Programming Approach: Stimgenics SCS Programming approach Using Intellis(TM) SCS system</description>
        </group>
        <group group_id="B2">
          <title>Control Arm</title>
          <description>Subjects randomized to this arm will receive control treatment&#xD;
Standard SCS Programming Approach: Standard SCS Programming approach Using Intellis(TM) SCS system</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="67"/>
            <count group_id="B2" value="61"/>
            <count group_id="B3" value="128"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.25" spread="12.16"/>
                    <measurement group_id="B2" value="60.66" spread="11.77"/>
                    <measurement group_id="B3" value="60.98" spread="11.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Back Pain</title>
          <description>Visual Analog Score (0.0cm to 10.0cm line). Higher score represents more pain.</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.25" spread="1.49"/>
                    <measurement group_id="B2" value="7.35" spread="1.26"/>
                    <measurement group_id="B3" value="7.3" spread="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Leg Pain</title>
          <description>Visual Analog Score (0.0cm to 10.0cm). Higher score represents more pain.</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.2" spread="2.58"/>
                    <measurement group_id="B2" value="6.58" spread="2.06"/>
                    <measurement group_id="B3" value="6.38" spread="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Individual Responders</title>
        <description>Percentage of Participants with a 50% decrease in back pain at 3 months compared to baseline. Pain rating will be measured on the 10 cm Visual Analog Scale (VAS). Change in back pain score will be used to determine individual responder (e.g., 50% reduction in VAS compared to Baseline VAS).</description>
        <time_frame>3 months</time_frame>
        <population>Intent to treat population (all subjects randomized)</population>
        <group_list>
          <group group_id="O1">
            <title>Test Arm</title>
            <description>Subjects randomized to this arm will receive test treatment&#xD;
Stimgenics SCS Programming Approach: Stimgenics SCS Programming approach Using Intellis(TM) SCS system</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>Subjects randomized to this arm will receive test treatment&#xD;
Standard SCS Programming Approach: Standard SCS Programming approach Using Intellis(TM) SCS system</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Individual Responders</title>
          <description>Percentage of Participants with a 50% decrease in back pain at 3 months compared to baseline. Pain rating will be measured on the 10 cm Visual Analog Scale (VAS). Change in back pain score will be used to determine individual responder (e.g., 50% reduction in VAS compared to Baseline VAS).</description>
          <population>Intent to treat population (all subjects randomized)</population>
          <units>percentage of responders</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.9" lower_limit="69.0" upper_limit="89.6"/>
                    <measurement group_id="O2" value="50.9" lower_limit="39.1" upper_limit="62.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Individual Responders</title>
        <description>The percentage of Individual Responders (50% reduction in pain score rated on a Visual Analog Scale); Test for superiority</description>
        <time_frame>3 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Back Pain Score</title>
        <description>Comparison of change from Baseline in back pain score (using Visual Analog Scale 0.0-10.0cm) determined at the 3- and 6-month visit after device activation, between test and control in a statistical test of non-inferiority. This is calculated as: Change from Baseline in Back Pain VAS = 3-Month Visit Pain VAS - Baseline Pain VAS.</description>
        <time_frame>3 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>6 Months Comparison of Back Pain Treatment Success</title>
        <description>Comparison of Back Pain Treatment Success (responder rate), measured as subjects with at least a 50% reduction in Back Pain Visual Analog Scale (VAS), evaluated at 6 months after device activation, between test and control</description>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oswestry Disability Index (ODI)</title>
        <description>Oswestry Disability Index (ODI) evaluated at 3 months visit</description>
        <time_frame>3 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>Frequency of treatment emergent adverse events</description>
        <time_frame>3 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>Adverse events related to the study is collected.</desc>
      <group_list>
        <group group_id="E1">
          <title>Test Arm</title>
          <description>Subjects randomized to this arm will receive test treatment&#xD;
Stimgenics SCS Programming Approach: Stimgenics SCS Programming approach Using Intellis(TM) SCS system</description>
        </group>
        <group group_id="E2">
          <title>Control Arm</title>
          <description>Subjects randomized to this arm will receive test treatment&#xD;
Standard SCS Programming Approach: Standard SCS Programming approach Using Intellis(TM) SCS system</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Medical device site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Implant Site Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>VP of Clinical Affairs</name_or_title>
      <organization>SGX Medical</organization>
      <phone>6613108409</phone>
      <email>wpark@sgxmedical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

